Drug Therapy in Obesity: A Review of Current and Emerging Treatments
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
Authors
Keywords
-
Journal
Diabetes Therapy
Volume 11, Issue 6, Pages 1199-1216
Publisher
Springer Science and Business Media LLC
Online
2020-04-16
DOI
10.1007/s13300-020-00816-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
- (2019) Ryota Usui et al. Journal of Diabetes Investigation
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
- (2019) Emily Brown et al. Obesity Reviews
- Comparative Efficacy of Bariatric Surgery in the Treatment of Morbid Obesity and Diabetes Mellitus: a Systematic Review and Network Meta-Analysis
- (2019) Chan Hyuk Park et al. OBESITY SURGERY
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
- (2019) Amar Ali et al. Diabetes Therapy
- Medical Devices in Obesity Treatment
- (2019) Aruchuna Ruban et al. Current Diabetes Reports
- The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
- (2019) David S. Mathiesen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
- (2019) Awadhesh Kumar Singh et al. Expert Review of Clinical Pharmacology
- Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
- (2019) David M. Williams et al. Diabetes Therapy
- Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes
- (2018) Sudha S. Shankar et al. DIABETES
- Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model
- (2018) IN YOUNG CHOI et al. DIABETES
- Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
- (2018) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Are peptide conjugates the golden therapy against obesity?
- (2018) S J Brandt et al. JOURNAL OF ENDOCRINOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
- (2018) R. Scott et al. PEPTIDES
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Recent updates on GLP-1 agonists: Current advancements & challenges
- (2018) Dilip Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes
- (2018) Alejandra Ramírez-Rodríguez et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Health Effects of Overweight and Obesity in 195 Countries over 25 Years
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials
- (2017) Amirhossein Sahebkar et al. PHARMACOLOGICAL RESEARCH
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
- (2017) Tinh-Hai Collet et al. Molecular Metabolism
- Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
- (2017) Sigrid Jall et al. Molecular Metabolism
- Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects
- (2016) William S. Denney et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
- (2016) Per Lundkvist et al. DIABETES OBESITY & METABOLISM
- Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
- (2016) Peter Kühnen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy
- (2015) Cristina Adelia Meehan et al. Expert Review of Clinical Pharmacology
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats
- (2014) Kim V. Andreassen et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Meta- and cost-effectiveness analysis of commercial weight loss strategies
- (2014) Eric A. Finkelstein et al. Obesity
- Cost-Effectiveness Analysis of Qsymia for Weight Loss
- (2014) Eric A. Finkelstein et al. PHARMACOECONOMICS
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
- (2014) Stephen C. Bain Diabetes Therapy
- Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications
- (2013) Theodore Kelesidis ANNALS OF INTERNAL MEDICINE
- Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
- (2013) Clifford J Bailey et al. BMC Medicine
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs
- (2013) E. W. Chan et al. Obesity Reviews
- Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials
- (2013) V. L. Gloy et al. BMJ-British Medical Journal
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- The medical care costs of obesity: An instrumental variables approach
- (2011) John Cawley et al. JOURNAL OF HEALTH ECONOMICS
- Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
- (2011) Chrysi Koliaki et al. Diabetes Therapy
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial
- (2010) Louis J. Aronne et al. Obesity
- New central targets for the treatment of obesity
- (2009) Bruce J. Sargent et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
- (2009) Eric Ravussin et al. Obesity
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started